Protective Effect of CoQ10 Against Negative Inflammatory Response and Organ Dysfunction in Cardiovascular Surgery (PANDA V)

Protective Effect of Coenzyme Q10 Against Negative Inflammatory Response and Organ Dysfunction in Cardiac and Aortic Surgery (PANDA V): a Randomized Controlled Trial

Status

Recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04444349

Acronym

PANDA

Enrollment

500

Registered

2020-06-23

Start date

2021-02-01

Completion date

2025-12-31

Last updated

2024-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease

Keywords

inflammatory response

Brief summary

Cardiovascular diseases are the leading causes of death and prescription drug use. Research on certain dietary supplements looks promising as a way to help reduce risk factors. Previous studies showed that CoQ10 levels were decreased in cardiovascular patients and worsening of mitochondrial dysfunction was observed. The overall objective of this study is to determine if supplementing with CoQ10 can reduce inflammatory risk factors in adults with cardiac surgery, independent of other dietary or physical activity changes.

Interventions

DRUGCoenzyme Q10

Coenzyme Q10 is a cardiovascular health supplement. It is a component of the electron transport chain and participates in aerobic cellular respiration, which generates energy in the form of ATP. The ingredients in Coenzyme Q10 help regulate the body's production of free radicals, strengthen the arteries and heart, and reverse oxidation.

DIETARY_SUPPLEMENTStandard Medical Therapy

Patients only received standard medical therapy without CoQ10.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Adult men and women * Who receive cardiovascular surgery * Agree to participate in the surgery and sign the informed consent form

Exclusion criteria

* Pregnant or planning on getting pregnant during the study * Contain a minimum of 2 traits of metabolic syndrome * Refused to participate in the surgery and refused informed consent

Design outcomes

Primary

Measure	Time frame	Description
C-reactive protein	Change from baseline of CRP in mg/L at 5 days after surgery.	Inflammatory and endothelial blood work biomarkers

Secondary

Measure	Time frame	Description
Interleukin-6	Change from baseline of IL-6 in pg/mL at 5 days after surgery.	Inflammatory and endothelial blood work biomarkers

Countries

China

Contacts

Primary ContactHong Liu, MD

dr.hongliu@foxmail.com8618801281613

Backup ContactYong-feng Shao, MD

yfshaojph@sina.com02568303101

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026